PYPD - PolyPid

https://www.polypid.com

Recent News

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

GlobeNewswire • 1 month ago • score: 0.33

Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding ...

Bullish

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - PolyPid ( NASDAQ:PYPD )

Benzinga • 2 months, 4 weeks ago • score: 0.23

The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ( "FDA" ) Approval of D-PLEX₁₀₀. The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.

52W High

$3.93

52W Low

$2.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.49

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.36

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.68

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

16.70%

Institutions (25–75% balanced)

34.45%

Shares Outstanding

15,897,200

Float

9,820,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-3.77

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.13%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—